



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

To,

Date: 30.05.2018

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 30.05.2018

Ref: Scrip Code 538965

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Concord Drugs Limited held on Wednesday, 30.05.2018 at 6:00 p.m. at the registered office of the company the following were considered and approved:

1. Audited financial results for the quarter and year ended 31.03.2018. **(Enclosed)**
2. Auditors Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2018. **(Enclosed)**

The meeting concluded at 8.00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited


For Concord Drugs Limited

S. Koni Reddy

Director

S. Koni Reddy
Whole-time Director & CFO
DIN: 02829319

Encl: as above



CONCORD DRUGS LIMITED


Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

Statement of Stand Alone Assets and Liability		
Particulars	As at March 31, 2018	As at March 31, 2017
ASSETS		
Non-current assets		
Property, plant and equipment	127,238,434	128,492,242
Investment property	7,859,768	7,859,768
Financial assets		
(a) Loans & Advances	8,849,430	11,454,533
(b) Trade receivables	498,206,121	156,548,452
Total Non - Current Assets	642,153,753	304,354,995
Current Assets		
Inventories	186,193,713	110,269,540
Financial assets		
(a) Investments		
(b) Trade receivables	213,516,909	105,766,711
(c) Cash and cash equivalents	407,551	1,714,303
(d) Bank balances other than (c) above	149,235	629,673
(e) Loans	11,983,822	8,441,354
Other current assets	9,733,866	24,083,454
Total Current assets	421,985,097	250,905,035
Total Assets	1,064,138,849.81	555,260,030
EQUITY AND LIABILITIES		
Equity		
Equity share capital	78,617,500	72,437,500
Other equity	114,614,094	117,489,293
Total Equity	193,231,594	189,926,793
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	34,085,018	61,757,973
Provisions	21,435,622	928,816
Deferred tax liabilities, net	2,123,495	2,736,329
Government Grants	6,174,854	6,848,397
Total Non-current liabilities	63,818,990	72,271,515
Current liabilities		
Financial liabilities		
(a) Borrowings	90,051,122	92,608,491
(b) Trade payables	663,683,309	163,646,576
Current tax liabilities, net	3,758,138	3,937,070
Other current liabilities	49,595,698	32,869,586
Total Current liabilities	807,088,267	293,061,723
Total liabilities	870,907,257	365,333,237
Total Equity and liabilities	1,064,138,849.81	555,260,030

For Concord Drugs Limited

S. Koni Reddy

Director



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2018

[Rs. in Lakhs]

Particulars	Quarterly ended				
	31-Mar-18			31-Mar-17	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I Revenue from Operations					
a. Net sales from Operations	2,109.55	596.12	2,143.08	5,179.72	5,748.97
b. Other Operating Income	-	-	-	-	-
II Other Income	18.13	1.21	2.72	13.58	15.03
III Total Revenue (I+II)	2,127.68	597.33	2,145.80	5,193.31	5,764.00
IV Expenses					
a. Cost of Material Consumed	2,020.46	262.15	1,708.19	4,650.17	4,650.89
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	66.78	(19.20)	308.00	320.38	(40.38)
c. Employees Benefit Expenses	27.69	55.96	104.41	197.42	280.65
d. Finance Costs	63.90	43.41	71.28	188.40	242.45
e. Depreciation and Amortisation expense	68.18	59.67	71.73	240.14	258.40
f. Other expenses	19.43	52.13	96.47	173.68	307.24
Total Expenses	2266.44	454.12	2360.08	5129.44	5699.25
Profit/ (Loss) before Exceptional Item and tax (III-IV)	-138.76	143.21	-214.28	63.87	64.75
V Exceptional Items					
VI Profit/ (Loss) before tax (V-VI)	-138.76	143.21	-214.28	63.87	64.75
VII Tax Expense:					
a. Current tax	(6.13)	15.22	(36.64)	31.45	48.79
b. Deferred tax charge/credit	0.00	15.22	-46.06	37.58	39.37
VIII Profit/ (Loss) for the period (VII-VIII)	-6.13	0.00	9.42	6.13	9.42
X Other Comprehensive Income	-132.63	127.99	-177.64	32.42	15.95
Items that will not be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	-132.63	127.99	-177.64	32.42	15.95
XI Paid-up equity share capital	786.18	786.18	724.38	786.18	724.38
(Face value of the share- Rs. 10 each)					
Other Equity	1,146.14	0.00	1,174.89	1,146.14	1,174.89
XII Earnings per share (of Rs. 10 each)					
XIII a. Basic (in Rs)	-1.69	1.63	-2.45	0.41	0.22
b. Diluted (in Rs)	-1.69	1.63	-2.45	0.41	0.22

For Concord Drugs Limited

S. Korri Reddy

Director



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsLtd@gmail.com, web : www.concorddrugs.in

- Notes:**
- The company has adopted Indian Accounting Standards (Ind AS) prescribed under Section 133 of the companies Act, 2013, read with the relevant rules issued thereunder from April 1,2017. The date of transition to Ind As is April 1, 2016 and accordingly, these financial statements have been prepared in accordance with the recognition and measurement policies laid down in Ind As 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening results and the comparative period figures have been reinstated accordingly.
 - The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on May 30,2018
 - The figures of the quarter ended March 31, 2018 and March 31,2017 are the balancing figures between Audited figures in respect of the full financial year upto March 31,2018 and March 31,2017 respectively and the unaudited published year to date figures upto December 31,2017 and December 31,2017 respectively, being the date of the end of the third quarter of the financial year. The standalone results for the 9 months ended December 31,2017 have been subjectively to the limited review by the statutory auditors, but the financial results and the other information for nine months ended December 31, 2016 have not been audited or reviewed by the statutory auditor. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide true and fair view of the company's affairs.
 - The reconciliation of net profit as previously reported (referred to as "Previous GAAP") and Ind As is as under :**


Particulars	Quarter ended March 31,2018
Net profit under Previous GAAP	- 132.63
Difference in measurement of Employee benefit expenses	-
Others	-
Net profit for the period under Ind AS	- 132.63
 - The reconciliation of equity under Previous GAAP and Ind As is as under :**

Particulars	As At March 31,2017
Equity reported under Previous GAAP	1,522.51
Derecognition of provision for proposed dividend and dividend tax thereon	-
Income on investments under amortised cost	-
Others	-
1. Unsecured loans to the extent considered to be converted into Equity	376.76
Equity under Ind AS	1,899.27
 - The company has allotted 6,10,000 equity shares of Rs. 10 each to the promoters. Consequent to the allotment the paid up share capital of the company has increased from 72,43,750 shares to 78,61,750 shares of Rs. 10 each
 - Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

By Order of the Board
FOR
For Concord Drugs Limited
S. Koni Reddy

Director
(Koni Reddy Seelam)
Director
DIN: 01764665

Place: Hyderabad
Date: May 30, 2018



CONCORD DRUGS LIMITED

Admin. Off: H.No. 3-11-1/1, Opp. Kamineni Hospital, L.B. Nagar, Hyderabad -500 074. (Telangana) INDIA.
Tel : (040)-24037763, Fax : (040)-24036379, E-mail : concorddrugsltd@gmail.com, web : www.concorddrugs.in

To,

Date: 30.05.2018

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, S. Koni Reddy, Whole-time Director & CFO of Concord Drugs Limited hereby declare that, the statutory Auditors of the company, M/s. NG Rao & Associates Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31st March, 2018.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

For Concord Drugs Limited

S. Koni Reddy

S. Koni Reddy Director
Whole-time Director & CFO
DIN: 02829319



Auditor's Report on Quarterly Financial Results and year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
M/s. Concord Drugs Limited.

We have audited the quarterly financial results of M/s. Concord Drugs Limited ("the Company") for the quarter ended 31st April 2018 and the year to date financial results for period from 01st April 2017 to 31st March 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly financial Results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements which have been prepared in accordance with recognition and measurements principles laid down in Accounting standard for interim Financial Reporting (AS 25), Prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting Principles generally accepted in India.

We conducted our audit in accordance with the auditing Standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2016 in the regard; and
- ii. give a true and fair view of the financial performance and other financial information for the quarter ended 31st March, 2018 as well as the year to date financial results for the period from 01st April 2017 to 31st March, 2018.

We did not audit the Results published by the company for the last three Quarters whose financial statements, other financial information have been reviewed by another auditor and whose reports have been furnished to us by the Management.

The financial results includes the results for the quarter ended 31st March, 2018 being the balancing figure audited between the audited figures in respect of the full financial year and audited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For N G RAO & ASSOCIATES
Chartered Accountants
FRNo.009399S



Partner: G Nageshwara Rao
Membership No.207300



Place: Hyderabad
Date: 30-05-2018